Onesource Specialty Pharma Limited (ONESOURCE) — Announcement | 18 August 2026

· NSE 🔴 High Importance Neutral
By StockFin Research Team AI-Assisted Analysis Source: BSE/NSE Filings
📢 Key Event
Credit rating upgraded to IND A/Positive with stable short-term rating
🔄 What Changed
Long-term rating upgraded from IND A- to IND A/Positive
🔮 What's Next
Positive Outlook
💡 Investor Takeaway
The upgrade signals improved creditworthiness and growth momentum for the company's core pharmaceutical operations.

India Ratings upgraded OneSource Specialty Pharma's long-term bank loan rating to IND A/Positive and affirmed the short-term rating at IND A1, reflecting strengthened business profile from commercial GLP-1 supply growth and improved cash flow visibility.

📄 View Original Announcement (PDF)

About Onesource Specialty Pharma Limited (ONESOURCE)

Healthcare · Pharmaceuticals · Listed on NSE

Market Cap: ₹17,366.55 Cr ROE: -0.8% ROCE: 0.9%

View full ONESOURCE stock details →

📡 Get AI alerts when ONESOURCE files next

Free • Daily 5 PM digest • Track filings, board meetings, and corporate actions

Track ONESOURCE — Free

📊 More ONESOURCE filings

See all ONESOURCE filings →

Source: Stock Announcements. Analysis by StockFin.ai. For informational purposes only — not investment advice.

Editorial & Data Transparency Notice

This analysis was programmatically compiled using StockFin AI utilizing official regulatory disclosures from the BSE and NSE. Content is automatically synthesized and audited against public financial filings. StockFin.ai is an educational research platform and is NOT a SEBI-registered investment advisor or research analyst.

📡 Get AI alerts when ONESOURCE files new disclosures

Track ONESOURCE filings, board meetings, and corporate actions. Free email alerts at 5 PM.

Track ONESOURCE — Free

Free account · 2 AI queries/day